Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04236-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Lingzi Yu und 12 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Gusu District, Suzhou, Jiangsu Province, China. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Agammaglobulinaemia Tyrosine Kinase, Programmed Cell Death 1 Receptor, Immunotherapy, Adoptive. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Gusu District, Suzhou, Jiangsu Province, China.
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Gusu District, Suzhou, Jiangsu Province, China.
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, No. 899, Pinghai Road, Gusu District, Suzhou, Jiangsu Province, China.
- Department of Pharmacy, The First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Gusu District, Suzhou, Jiangsu Province, China.
- The First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Gusu District, Suzhou, Jiangsu Province, China. wudepei18@163.com.
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Gusu District, Suzhou, Jiangsu Province, China. wu…
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
Zitieren
APA
Yu, L., Ping, N., Zou, R., Zhu, Q., Li, J., Zhang, X., Xia, F., He, J., Tu, J., Kong, D., Wu, D., Jin, Z., & Qu, C. (2025). Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04236-4
Vancouver
Yu L, Ping N, Zou R, Zhu Q, Li J, Zhang X, et al. Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04236-4
BibTeX
@article{Yu2025,
author = {Yu, Lingzi and Ping, Nana and Zou, Rui and Zhu, Qian and Li, Junhong and Zhang, Xiao and Xia, Fan and He, Jiajie and Tu, Jiajie and Kong, Danqing and Wu, Depei and Jin, Zhengming and Qu, Changju},
title = {Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04236-4}
}
EUVIMED